sattva neelapu, md, explains what the results of zuma-1 mean to dlbcl patients
Published 7 years ago • 46 plays • Length 1:17
Download video MP4
Download video MP3
Similar videos
-
1:18
sattva neelapu, md, tells us about the results of the zuma-1 study in dlbcl presented at ash 2019
-
1:23
sattva neelapu, md, discusses efficacy results of the zuma-1 trial
-
1:41
sattva neelapu, md, regarding the zuma-1 two-year follow-up study in dlbcl
-
1:03
sattva neelapu, md, discusses the results of the zuma-1 pivotal phase 2 study with kte-c19
-
0:32
sattva neelapu, md shares safety results of the zuma-1 trial in patients with nhl
-
3:48
sattva neelapu, md, discusses details of the zuma-12 trial presented at ash 2020
-
4:28
what is lymphoma?
-
6:24
"diagnosis of lymphoma, basic guidelines" by dr. t. p. sahoo
-
1:05:04
biology of lymphoma presented by dr samar issa
-
1:34
dr. neelapu on interim results of the phase ii zuma-1 study in dlbcl
-
6:21
sattva s. neelapu, md: encouraging results for car t-cells in refractory dlbcl
-
2:13
sattva neelapu | ash 2018 | results from the two-year follow-up of zuma-1
-
1:16
dr. neelapu on zuma-1 trial design of kte-c19
-
1:33
sattva neelapu, md, on real-world experience & clinical studies examining axicabtagene ciloleucel
-
1:37
sattva neelapu, md, considers the use of axicabtagene ciloleucel with elderly lymphoma patients
-
1:01
sattva neelapu, md, on the possibility to enhance t-cell proliferation for a higher response rate
-
0:46
key takeaway from 2-year follow-up data of zuma-1 trial in large b-cell lymphoma
-
2:59
axi-cel in older patients: data from zuma-1 and clinical use
-
2:17
zuma-12: axicabtagene ciloleucel as a first-line therapy in patients with high-risk lbcl
-
1:06
sattva neelapu, md, on when we may see widespread availability of car-t therapies
-
2:02
dr. neelapu on updated zuma-1 findings in non-hodgkin lymphoma
-
1:44
comparison of zuma-1 and scholar-1 outcomes
Clip.africa.com - Privacy-policy